Kimia Biosciences Ltd
Fundamental Score
Kimia Biosciences Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of KIMIABL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (186.78%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (41.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 16.76 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Strong Revenue Growth (20.65%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Excellent EPS Growth (46.61% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (47.21% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Balanced Promoter Holding (74.94%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
9 factors identified
Margin Pressure Concerns (3.90%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Profit Decline Concern (-36.65%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Limited Growth History (2.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Elevated Debt Levels (D/E: 3.11)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Limited Institutional Interest (FII+DII: 0.38%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High Debt-to-Equity Ratio
Observation: Elevated financial risk due to high leverage.
Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.
Very High Debt Levels
Observation: Excessive leverage may strain cash flows.
Analysis: Debt-to-equity above 2.0 indicates potential financial distress risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Kimia Biosciences Ltd
About KIMIABL
Business Overview
Kimia Biosciences Limited manufactures and sells active pharmaceutical ingredients (APIs) in India. The company offers and develops APIs in the categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, lipid lowering agents, vitamin, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, and anti-bacterial, as well as anti-psychotic, anti-fungal, urologicals, anti-inflammatory, prokinetic agent, cholelithiasis agent, anti-asthmatic, anti-depressant, anti-acne, decongestant, and anti-virals. It exports its products. Kimia Biosciences Limited was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019. The company was incorporated in 1993 and is based in New Delhi, India.
Company Details
Key Leadership
KIMIABL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Kimia Biosciences Ltd (KIMIABL)?
As of 09 Feb 2026, 12:16 pm IST, Kimia Biosciences Ltd (KIMIABL) is currently trading at ₹32.64. The stock has a market capitalization of ₹137.11 (Cr).
Is KIMIABL share price Overvalued or Undervalued?
KIMIABL is currently trading at a P/E ratio of 16.76x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Kimia Biosciences Ltd share price?
Key factors influencing KIMIABL's price include its quarterly earnings growth (Sales Growth: 20.65%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Kimia Biosciences Ltd a good stock for long-term investment?
Kimia Biosciences Ltd shows a 5-year Profit Growth of 47.21% and an ROE of 186.78%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 3.11 before investing.
How does Kimia Biosciences Ltd compare with its industry peers?
Kimia Biosciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare KIMIABL's P/E of 16.76x and ROE of 186.78% against the industry averages to determine its competitive standing.
What is the P/E ratio of KIMIABL and what does it mean?
KIMIABL has a P/E ratio of 16.76x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹17 for every ₹1 of annual earnings.
How is KIMIABL performing according to Bull Run's analysis?
KIMIABL has a Bull Run fundamental score of 52.6/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does KIMIABL belong to?
KIMIABL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Kimia Biosciences Ltd.
What is Return on Equity (ROE) and why is it important for KIMIABL?
KIMIABL has an ROE of 186.78%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Kimia Biosciences Ltd generates profits from shareholders' equity.
How is KIMIABL's debt-to-equity ratio and what does it indicate?
KIMIABL has a debt-to-equity ratio of 3.11, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is KIMIABL's dividend yield and is it a good dividend stock?
KIMIABL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has KIMIABL grown over the past 5 years?
KIMIABL has achieved 5-year growth rates of: Sales Growth 2.27%, Profit Growth 47.21%, and EPS Growth 46.61%.
What is the promoter holding in KIMIABL and why does it matter?
Promoters hold 74.94% of KIMIABL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is KIMIABL's market capitalization category?
KIMIABL has a market capitalization of ₹137 crores, placing it in the Small-cap category.
How volatile is KIMIABL stock?
KIMIABL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for KIMIABL?
KIMIABL has a 52-week high of ₹N/A and low of ₹N/A.
What is KIMIABL's operating profit margin trend?
KIMIABL has a 5-year average Operating Profit Margin (OPM) of 3.90%, indicating the company's operational efficiency.
How is KIMIABL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 20.65% and YoY Profit Growth of -36.65%.
What is the institutional holding pattern in KIMIABL?
KIMIABL has FII holding of 0.00% and DII holding of 0.38%. Significant institutional holding often suggests professional confidence in the stock.